INCAGN02390, a Novel Antagonist Antibody That Targets the Co-Inhibitory Receptor TIM-3

Jeremy Wright,1 Priyadarshini Iyer,1 Ekaterina Breeus-Nystrom,1 Christina Riordan,1 David A. Savitsky,1 Mark Findeis,1 Dennis Underwood,1 Joseph Connolly,1 Benjamin Morin,1 Michele Sanicola-Nadel,1 Horacio Nasrili,2 Peggy Scherer,1 Gregory Hollis,3 Reid Huber,4 Robert Stein,1 Marc van Dijk,1 Jennifer Buell,1 Nicholas S. Wilson1

Key words: antibody-drug conjugates, TIM-3, CAR, ADC

INCAGN02390 is a novel antagonist antibody (aNovA) targeting the co-inhibitory receptor, TIM-3. This poster presents a novel antibody drug conjugate (ADC) incorporating a payload of the antimitotic drug monomethyl auristatin E (MMAE). In a human tumor microenvironment (TME) model, INCAGN02390 + anti-CD19 antibody (A) demonstrated increased efficacy compared to anti-CD19 antibody alone. In patients with hematologic malignancies and solid tumors, our preclinical data suggests that INCAGN02390 may provide a new treatment option for patients with CD19− tumors.

Abstract

INCAGN02390 is a novel aNovA targeting the co-inhibitory receptor, TIM-3. This antibody-drug conjugate (ADC) incorporates the antimitotic payload monomethyl auristatin E (MMAE). In a human tumor microenvironment (TME) model, INCAGN02390 + anti-CD19 antibody demonstrated increased efficacy compared to anti-CD19 antibody alone. In patients with hematologic malignancies and solid tumors, the preclinical data suggests that INCAGN02390 may provide a new treatment option for patients with CD19− tumors.

INCAGN02390 Demonstrates Dose-Dependent Binding to TIM-3 and Blockade of PS-TIM-3 Interactions

In a monomethyl auristatin E (MMAE) concentration-dependent manner, INCAGN02390 inhibited binding to TIM-3. TIM-3 was internalized and meditated increased Efficacy With an anti-TIM-3 antibody in combination with anti-PD-1.

INCAGN02390 Elicits Rapid Internalization of TIM-3

In a MMAE concentration-dependent manner, INCAGN02390 inhibited binding to TIM-3. TIM-3 was internalized and meditated increased Efficacy With an anti-TIM-3 antibody in combination with anti-PD-1.

INCAGN02390 Co-operates With Anti-PD-1 to Enhance T-Cell Function

In a MMAE concentration-dependent manner, INCAGN02390 inhibited binding to TIM-3. TIM-3 was internalized and meditated increased Efficacy With an anti-TIM-3 antibody in combination with anti-PD-1.

Conclusions

INCAGN02390 is a novel antibody-drug conjugate (ADC) incorporating a payload of the antimitotic drug monomethyl auristatin E (MMAE). In a human tumor microenvironment (TME) model, INCAGN02390 + anti-CD19 antibody demonstrated increased efficacy compared to anti-CD19 antibody alone. In patients with hematologic malignancies and solid tumors, the preclinical data suggests that INCAGN02390 may provide a new treatment option for patients with CD19− tumors.